PFE is trading 2% down today at $24.23, extending its recent multi-day slide. Investors are reacting to: - Mixed topline Phase 3 results for Pfizer's investigational lung cancer drug, sigvotatug vedotin, which missed its primary overall survival endpoint in a late-stage trial. - Lingering concerns regarding guidance and the product pipeline continue to weigh on sentiment.